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Changes in the Expression of Thin Filament-Associated Proteins in Colonic 
Smooth Muscle from Mice during Inflammation 
 
By 
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Virginia Commonwealth University, 2011 
 
Director: S. Murthy Karnam, Ph.D. 
Professor, Department of Physiology and Biophysics 
 
The contractility of smooth muscle in inflammatory bowel disease and experimental colitis is 
reduced due to inhibition of neurotransmitter release and a decrease in the response of smooth 
muscle to contractile agonists.  We and others have shown that inflammation induced by TNBS 
treatment alters the expression and/or activity of signaling molecules involved in the regulation 
of Ca
2+
 mobilization, MLC20 phosphorylation and contraction in colonic smooth muscle.  
Although, thin filament- associated proteins such as calponin, caldesmon, tropomyosin and 
smoothelin do not directly participate in contraction, they regulate acto-myosin interaction and 
thus, muscle contraction.  Calponin, caldesmon and tropomyosin inhibit actomyosin interaction 
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and the inhibition is relieved upon phosphorylation of these proteins.  Recent studies have shown 
that visceral smooth muscle from smoothelin knockout mice exhibited decreased contraction.  
However, the effect of inflammation on the expression of thin filament- associated proteins is not 
known.  The aim of the present study is to determine the changes in the expression of calponin, 
caldesmon, tropomyosin, and smoothelin in colonic circular smooth muscle from TNBS- and 
DSS-induced colitis in mice.  The animals were euthanized on day 3 and a segment of inflamed 
distal colon was removed. Colonic muscle strips from colitis mice and control mice were 
dissected for western blot and real-time RT-PCR analysis; contraction was measured by scanning 
micrometry in cells isolated from the muscle strips. Contraction in response to acetylcholine in 
muscle cells isolated from colonic muscle strips derived from mice with TNBS colitis was 
significantly inhibited compared with the response of cells derived from untreated colon or colon 
treated with ethanol.  Expression of α-actin, γ-actin calponin, caldesmon, smoothelin-A and 
tropomyosin mRNA in muscle strips from TNBS or DSS colitis was significantly increased 
compared to control animals.  Similarly, expression of α-actin, calponin, caldesmon, smoothelin-
A and tropomyosin protein as determined by western blot was significantly increased compared 
to control animals.  We conclude that the expression of α-actin, γ -actin calponin, caldesmon, 
smoothelin-A and tropomyosin is upregulated in colonic circular smooth muscle from TNBS or 
DSS colitis.  Increase in the expression of calponin, caldesmon and tropomyosin, which act to 
inhibit acto-myosin interaction, could contribute to decrease in smooth muscle contraction.   
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CHAPTER 1: INTRODUCTION 
 
 
1.   SMOOTH MUSCLE 
Smooth muscle has wide distribution in the body.  The contractile activity of smooth 
muscle is critical for normal physiology of vascular system, respiratory system, gastrointestinal 
system and the genitourinary systems. Malfunction of smooth muscle in these systems leads to a 
variety of clinical disorders. To mediate the contractile function smooth muscle expresses 
selective catalog of genes that define the smooth muscle cells from other cell types.   The main 
contractile apparatus in the smooth muscle consists of two types of filaments: thin filaments and 
thick filaments (28, 29, 38, 67, 69, 90, 91).  Thin filaments consist of ~42 kDa protein actin, 
which exists in vivo as filamentous actin (F-actin), and associated proteins such as caldesmon, 
calponin, tropomyosin and smoothelin.  Smooth muscle contains similar amounts of actin as 
skeletal muscle.  Thick filaments are aggregates of myosin molecule, the molecular motor of all 
muscles.  Each myosin molecule is a hexamer consisting of a pair of myosin heavy chain 
(MHC), a pair of 17-kDa essential light chains, and a pair of 20-kDa myosin light chains 
(MLC20).  Each MHC is asymmetric and contains a globular head at the N-terminus and a 
coiled-tail at the C-terminus.  The globular head contains ATP binding site, actin binding site 
and intrinsic ATPase activity (28, 67).   The interaction of actin with myosin and subsequent 
hydrolysis of ATP is the fundamental reaction whereby chemical energy is converted into 
mechanical energy.  This interaction generates force and shortens muscle as a result of the 
2 
 
sliding of overlapping, interdigitating thin and thick filaments. Smooth muscle contains less 
myosin than skeletal muscle, but generates as much force as striated muscle. Alternative splicing 
of smooth muscle MHC produces 2 C-terminal isoforms (SM1 and SM2) and 2 N-terminal 
isoforms (SM-A and SM-B).  The SM1 isoform has been demonstrated to form better contractile 
filaments compared to SM2 isoform, whereas the SM-B isoform is associated with increased 
myosin ATPase activity and increased shortening velocity, a characteristic of phasic phenotype 
of smooth muscle, compared with the SM-A isoforms (28, 67). 
“Excitation-contraction coupling” in all muscle is initiated by increase in intracellular Ca2+ 
leading to changes in the activity of, or interactions of, actin and myosin.  However, the 
contraction of smooth muscle is far more than a simple calcium switch and involves complex, 
and often redundant, signaling pathways that lead to actomyosin interaction.  The fine-tuning of 
smooth muscle function is made possible mainly because of the dependent acto-myosin 
interaction on 20-kDa myosin light chain (MLC20) phosphorylation at Ser19, which is both 
necessary and sufficient for acto-myosin interaction (28, 29, 38, 67, 69, 81, 89-91).  
Phosphoryaltion and dephophorylation of MLC20 are directly correlated to smooth muscle 
contraction and relaxation, respectively, and the levels of MLC20 phosphorylation are regulated 
by MLC kinase (MLCK) and MLC phosphatase (MLCP) activity.  The complex mechanisms 
that regulate MLC20 phosphorylation and acto-myosin interaction include: 1) mechanisms that 
regulate acto-myosin interaction through changes in MLC20 phosphorylation levels; 2) 
mechanisms that regulate directly acto-myosin interaction via a set of proteins associated with 
actin; and 3) mechanisms that regulate cytoskeleton remodeling and transmission and 
maintenance of force developed by acto-myosin interaction (67).     
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1.1. Mechanisms involved in the regulation of MLC20 phosphorylation.   
1.1.1. MLCK: An essential step in smooth muscle contraction is phosphorylation of the 
MLC20 at Ser19, which increases significantly the actin-activated myosin ATPase activity (67, 
69, 90, 91).  To date, the best-characterized and physiologically important pathway in MLC20 
phosphorylation is Ca2+/calmodulin(CaM)-dependent activation of MLCK in response to 
increase in intracellular Ca
2+
 by contractile agonists (38).  In vitro studies suggest that MLC20 
phosphorylation at Ser19 is also regulated by Ca
2+
-independent kinases such as integrin-linked 
kinase (ILK), zipper interacting protein kinase (ZIPK) and Rho kinase (69, 90, 91).  The 
physiological significance of these kinases in terms of MLC20 phosphorylation, however, 
remains unclear. MLCK is strictly dependent on Ca2+/CaM for its activation. Stimulation of 
smooth muscle by contractile agonists elevates the intracellular concentration of Ca
2+
 ([Ca
2+
]i) 
via activation of voltage-gated Ca
2+
 channels, and/or IP3 receptors/Ca2+ channels and causes 
Ca
2+
 to bind to calmodulin (CaM).  The affinity of MLCK for CaM is strongest among the CaM-
dependent protein kinases (38, 98).  There are three isoforms of MLCK: ubiquitous smooth 
muscle MLCK (smMLCK), restricted cardiac muscle MLCK (cMLCK) and skeletal muscle 
MLCK (skMLCK). MLCK of smooth muscle consists of an N-terminal actin-binding domain, C-
terminal myosin-binding domain and a central catalytic domain that phosphorylates MLC20.  The 
region between the catalytic domain and C-terminal domain has been characterized as the 
regulatory domain for kinase activity.  Due to the interaction of MLCK with actin and myosin, it 
is proposed that a mechanism, referred as non-kinase activity of MLCK regulated acto-myosin 
interaction, however, the physiological significance of non-kinase activity of MLCK is unknown.  
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Targeted deletion of MLCK in smooth muscle leads to decreased gut motility, urinary bladder 
function, and blood pressure, and also significant reduction in MLC20 phosphorylation in 
response to contractile agonist. Changes in the expression and/or activity of Ca
2+
 mobilization 
and MLCK regulation pathways lead altered muscle contraction.   
 
1.1.2. MLCP: The [Ca
2+
]i transient responsible for the activation of MLCK is rapidly and 
efficiently dissipated by Ca
2+
 extrusion from the cell and uptake into sarcoplasmic Ca
2+
 stores. 
This leads to rapid decline in MLCK activity.  MLCK activity is also regulated by several 
kinases such as Ca
2+
/calmodulin-dependent protein kinase II, p21-activated protein kinase 1 
(PAK1) or AMP-dependent kinase (38, 69).  Phosphorylation of MLCK by these kinases 
decreases the affinity for Ca2+/CaM and inhibits the activity.  However, agonist-induced MLC20 
phosphorylation and contraction are maintained in the absence of elevated [Ca
2+
]i  and MLCK, 
and mechanisms responsible for this are largely correlated to inhibition of MLCP.  After 
phosphorylation of MLC20 by MLCK, MLC20 is dephosphorylated by MLCP, the activity of 
which is regulated by Ca2+-independent mechanisms often referred as Ca2+-sensitization.  The 
sustained contraction does not reflect Ca
2+
 sensitization to low levels of Ca
2+
, because complete 
inhibition of MLCP in the absence of Ca
2+
 induces smooth muscle contraction.  This contraction 
induced by MLCP inhibitors in the absence of Ca
2+
 is blocked by high concentrations of non-
specific kinase inhibitors such as staurosporine, implying participation of Ca2+-independent 
MLCK kinases, probably ZIP kinase. Intracellular pathways linking receptor activation and 
Ca2+-independent contraction have been investigated in several laboratories and identification of 
pathways was greatly facilitated by the use of highly selective, cell permeable Rho kinase 
inhibitor, Y27632 (69).  The pathways in Ca2+-independent contraction involve G protein 
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activation, MLC20 phosphorylation by a Ca2+-independent protein kinase and inhibition of MLC 
phosphatase via Rho kinase and/or protein kinase C (PKC).  MLCP holoenzyme is hetertrimer 
consisting of a 37-KDa catalytic subunit of type 1 phosphatase (ppicδ), a 110- to 130-KDa 
regulatory subunit, known as myosin phosphatase target subunit I or MYPT1, and a 20-kDa 
subunit of unknown function (29).  Selectivity of PP1 catalytic subunit for myosin is conferred 
by the targeting subunit and this subunit potentiates dephosphorylation of MLC by the catalytic 
subunit.  MYPT1 is abundantly expressed in smooth muscle and alternative splicing of two 
exons gives rise to four major MYPT1 isoforms that differs in the presence of a central insert 
and/or a leucine zipper motif at the C-terminal end of the protein (LZ+ and LZ− isoforms). 
Phosphorylation of MYPT1 in its C-terminus half at Thr
696
 or Thr
853 
by Rho kinase or ZIP kinase 
fosters dissociation and inhibits activity of the catalytic subunit and, thus MLC20 
dephosphorylation (68, 90, 91).  MLCP catalytic activity is also dependent on an endogenous 
phosphorylation-dependent inhibitor, CPI-17 (PKC-potentiated PP1 inhibitory protein of 17 
kDa), which is preferentially expressed in smooth muscle.  Phosphorylation of CPI-17 at Thr38 
by PKC, and probably by other kinases such as Rho kinase, ZIPK or ILK, greatly augments the 
inhibitory effect (69, 89- 91, 98).  CPI-17 is phosphorylated in response to contractile agonists 
and the phosphorylation is correlated with Ca2+-independent contraction.   Thus, MLCP activity 
is tightly regulated by Rho kinase/MYPT1 and PKC/CPI-17 pathways and these pathways have 
significant impact on MLC20 phosphorylation and muscle contraction.  Changes in the 
expression and/or activity of Rho kinase/MYPT1 and PKC/CPI-17 pathways lead altered muscle 
contraction.   
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1.2. Mechanisms involved in the regulation of acto-myosin interaction by thin-filament 
associated proteins 
Contraction is initiated by MLC20 phosphorylation, however, it can be modulated by 
other mechanisms, one of which involves the thin-filament associated proteins (15, 28, 59, 67).  
In smooth muscle, the predominant thin-filament protein actin exists as polymerized elongated 
filament (F-actin) and accounts for 30-50% of total non-collagenous protein.  Associated with 
actin are tropomyosin, caldesmon, calponin and smoothelin.  
1.2.1. Tropomyosin.  Tropomyosin is a coiled-coil -helix and cooperates the contractile 
filament interaction by virtue of its spanning seven-actin monomers. It has been shown that 
binding of myosin to actin leads to movement of tropomyosin and this process is facilitated by 
phosphorylation of myosin suggesting a possible participation of tropomyosin in acto-myosin 
interaction (28, 67).  Tropomyosin also facilitates inhibition of acto-myosin ATPase activity by 
caldesmon. 
1.2.2. Caldesmon.  Caldesmon is a highly conserved protein that binds actin, myosin, 
tropomyosin and calmodulin and exists as smooth muscle-specific h-caldesmon and non-muscle 
l-caldesmon.  Caldesmon binds to myosin via N-terminal domain and tethers to actin in 
conjunction with C-terminal actin binding domain.  Binding of caldesmon to actin causes 
inhibition of acto-myosin ATPase activity and suggested to play a role in suppressing contractile 
tone.  Phosphorylation of caldesmon by ERK1/2 or PKC and binding of Ca2+/CaM to the C-
terminal domain of caldesmon in response to contractile agonist appear to reverse the inhibitory 
actions of caldesmon (6, 27, 67).   
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1.2.3. Calponin.  Calponin is an actin-binding protein and exists as smooth muscle-
specific basic h1-calponin, cardiac muscle predominant neutral h2-calponin, and acidic calponin 
that is not tissue-specific (12, 28, 67).  The role of calponin in the regulation of smooth muscle 
contraction appears to be distinct and tissue-specific. In the urinary bladder and vas deferens of 
calponin knockout mice, a faster shortening velocity was noticed consistent with the hypothesis 
that calponin is an inhibitor of acto-myosin ATPase activity.  In contrast, in tonic vascular 
smooth muscle suppression of calponin caused a decrease in agonist-induced contraction, 
suggesting a stimulatory effect of calponin on smooth muscle contraction.  Calponin was also 
shown to acts as scaffold tethering ERK1/2 and PKC pathways to regulate smooth muscle 
contraction.  
1.2.4. Smoothelin.  Smoothelin is abundantly expressed actin-binding protein and exists 
as visceral smooth muscle-specific smoothelin-A and vascular smooth muscle-specific 
smoothelin-B (72, 84).  Although smoothelin has been used as a marker for contractile 
phenotype of smooth muscle, knowledge on its role in the regulation of smooth muscle 
contraction is limited.  A role for smoothelin was suggested recently using smoothelin knockout 
mice, which demonstrated decreased contraction in response to contractile agonists, however, the 
exact mechanism by which smoothelin regulates muscle contraction is not known.    
Thus, the importance of thin-filament associated proteins in the regulation of contraction appears 
to vary and tissue-specific.  Changes in the expression thin-filament associated proteins may 
lead to altered muscle contraction (99).   
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1.3. Mechanisms involved in the regulation of cytoskeletal remodeling  
In smooth muscle, the non-muscle isoform of actin (e.g., β-actin and γ-cytoplasmic actin) 
are associated with cytoskeleton.  Studies demonstrating the remodeling of cytoskeleton in 
response to contractile agonist raise the possibility that actin cytoskeleton is dynamic and the 
cytoskelton remodeling may regulate smooth muscle contraction (67).  However, much remains 
to be determined regarding the organization of the contractile filaments with respect to the 
overall cytoskeleton and the mechanism by which the cytoskeleton remodeling regulates acto-
myosin interaction.  Several hypotheses have proposed which include increase in the strength of 
connections between membrane adhesion junctions and actin filaments and facilitating the 
transmission of force. 
2.  INFLAMMATION 
Inflammatory bowel diseases are multifactorial in nature and thought to occur as a result 
of complex interactions between the immune system and environmental factors.  Ulcerative 
colitis and Crohn’s disease are the two main inflammatory bowel diseases (IBD) that are 
associated with intestinal inflammation.  Patients with IBD have altered bowel habits due to 
changes in mucosal secretory and absorptive functions as well as colonic motility.   Although the 
causes of IBD are not fully understood, studies in patients and using animal models suggest that 
there is an initial immunological insult that is followed by a dysregulated immune response.  
Intestinal homeostasis is coordinated by the responses of different cell types, including both 
immune and non-immune cells such as epithelial cells, enteric neurons, interstial cells of Cajal 
(ICC) and smooth muscle cells.    The interaction between immune and nonimmune cells is 
amplified during inflammation due to release of many proinflammatory cytokines (e.g., 
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interleukin (IL)-1β and tumor necrosis factor (TNF-α) both by immune cell and non-immune 
cell, and contribute to the amplification of tissue injury. 
2.1. Animal models   
A number of animal models of gastrointestinal inflammation have been developed to 
characterize the mechanisms underlying pathogenesis of inflammatory bowel diseases. Although 
often suspected for not mimicking all the features of IBD due to its multifactorial nature, it is 
generally considered that many mouse models of intestinal inflammation resemble aspects of 
IBD in humans and provided important insights into the mechanisms that control intestinal 
homeostasis and regulate intestinal inflammation, albeit with some limitations (7, 40, 46, 50, 57, 
61-63). To date, there are more than 50 mouse models of intestinal inflammation.   The most 
widely used animals models are parasitic infection with Trichinella spiralis, and the hapten 
2,4,6-trinitrobenzene sulphonic acid (TNBS) and dextran sodium sulphate (DSS) models of 
colitis (50, 57, 61-63, 92, 100-103).  Intracolonic instillation of a solution of TNBS in ethanol 
causes transmural inflammation due to a delayed type hypersensitivity reaction which involves a 
T-helper (Th)1 immune response, whereas the immune response to nematode infection involves 
Th2 cytokine production.  Acute DSS colitis has a Th1 type cytokine profile, but more chronic 
model involves features of both Th1 and Th2 immune responses.   
2.2. Colonic dysmotility     
Both in vivo and in vitro studies in patients and animal models of colitis support the idea 
that colitis is accompanied by a decrease in the contractility of smooth muscle from the inflamed 
area (16, 27, 40-49, 79, 90).  Measurements of in vivo motility patterns in dogs during acetic 
acid-induced ileitis, and in rats with acute DSS-induced colitis demonstrated that inflammation 
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decreased the frequency of migrating motor complexes and tone.  Since the giant migrating 
contractions are responsible for movements of the faecal pellets, it was suggested that 
inflammation reduces propulsive motility (62, 71, 78).  Similar decrease in pellet propels in vitro 
in distal colon was observed in TNBS-induced colitis.  A decrease in the spontaneous contractile 
activity, and receptor- and non-receptor-mediated contractions were also observed during 
inflammation (27).  The changes in motility are regardless of the model used to induce 
inflammation that is administration of different chemical compounds such as TNBS, DSS and 
acetic acid.  Many studies were performed in animal models of gastrointestinal inflammation in 
order to elucidate the mechanisms underlying gut dysmotility during inflammatory processes. 
These studies have generated a number of concepts that provide insight into how the immune 
and motor systems of the gut interface and also clearly demonstrated how the inflammation of 
the mucosa causes colonic dysmotility.  The mechanisms underlying the colonic dysmotility are 
complex and involve multiple mechanisms such as changes in enteric neurotransmission (17-22, 
25, 63, 82), afferent sensory input (5, 8, 65), interstitial cells of Cajal (87), and abnormalities of 
the effector itself, the enteric smooth muscle intrinsic smooth muscle contractility (1-4, 31, 32, 
35-37, 57, 93-96).   In addition, studies in animal models of inflammation have suggested that 
changes in enterochromaffin cell number and 5-HT release and reuptake result in colonic 
dysmotility (49, 50, 55). 
2.2.1. Enteric Nervous system.  The neurons and the glia of the myenteric plexus, which 
is located between the longitudinal and circular smooth muscle layers of the muscularis externa, 
and the submucosal plexus, which is located in the submucosa constitute the enteric nervous 
system (9-11, 26).  Because of the importance of ENS in gut functions, several studies have 
focused on changes in ENS and structure and function in patients with IBD or in animal models 
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of gut inflammation (7-9, 24, 30, 47-56, 64, 73).  The nature of the changes in the ENS in IBD 
appear to be dependent on the disease (Crohn's vs. ulcerative colitis), the region of the intestinal 
wall and whether or not the tissue was from a site of active inflammation.  Both the structure and 
function of the enteric nervous system (ENS) are substantially altered in enteric inflammation.  
These include a significant decrease in the number of myenteric and submucosal neurons during 
colitis, ganglion cell and axonal degeneration and necrosis, and impaired release of 
neurotransmitters acetylcholine, noradrenaline, and nitric oxide.   Because of their projections to 
the mucosal layer, where inflammation is centered, AH neurons, which serve as primary afferent 
and interneuronal functions, appear to be more susceptible to inflammation (51, 52).  Studies in 
patients with IBD and in animal models of inflammation revealed that the immunoreactivity of 
vanilloid receptor TRPV1, an integrator of noxious/inflammatory stimuli on sensory nerves that 
contributes to inflammation-induced sensory dysfunction, is greatly increased in colonic nerve 
fibers (10, 24, 60).  Many of these changes in the structure and function are implicated in altered 
sensory, secretory and motor function of the intestine during inflammation.  Inflammatory 
cytokines and infiltrating immune cells are responsible for many of the changes to the ENS in 
inflammation.  The extent of damage to ENS function depends on the animal model and species, 
probably due to differences in the pathogenesis of inflammatory conditions.  Studies also 
indicate that neuronal changes are not limited to the region of inflammation, but can occur in 
regions proximal or distal to the site of inflammation (71).  Thus, plasticity of ENS is a feature of 
intestinal inflammation and several potentially relevant mechanisms underlying ENS plasticity 
have also been studied including the role of neurotrophins and enteric glia.  
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2.2.2. Interstitial cells of Cajal (ICC).  ICC are mesenchymal cells with small cell 
bodies and several elongated processes and express c-kit, the proto-oncogene that encodes the 
receptor tyrosine kinase, kit. ICC present between longitudinal and circular muscle layers (ICC-
MY) are spontaneously active and generate slow wave depolarization in different parts of the GI 
tract, and are important as pacemakers.  Changes in the number of ICC and ultrastructure were 
reported in animal models of colitis and in patients with Crohn’s disease and ulcerative colitis 
(87).  The reduction in ICC number was associated with an inhibition of spontaneous 
contractions of colon. However, more studies of colonic pacemaker activity in IBD are needed 
for further insight on the role of ICC in colonic dysmotility.   
2.2.3. Smooth muscle.  The smooth muscle cells of the gastrointestinal tract are the final 
effectors of force development and work.  Smooth muscle cells are capable of synthesizing and 
secreting a variety of pro- and anti-inflammatory mediators, including cytokines, chemokines, 
growth factors, and cell-adhesion molecules that contribute to the maintenance and resolution of 
the inflammatory response in the gut (88, 96, 97).  Thus, smooth muscle cells act as both source 
and target of these mediators.  Substantial changes to smooth muscle structure and function have 
also been shown in intestinal inflammation. Studies have shown that inflammatory mediators 
either decrease or increase smooth muscle contractility and the response appears to be tissue- and 
cytokine-specific (1-4, 85, 92-96).  Inflammation induced by helminth infection resulted in 
hypercontractility of longitudinal muscle via IL-4 and IL-13, whereas inflammation induced by 
TNBS or DSS resulted in hypocontractility of circular muscle via IL-1β, TNF-α or ICAM-1.  
Several targets in the signaling pathways mediating contraction that are affected by inflammatory 
cytokines have been identified and the changes in the expression or activity of these targets are 
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linked to altered muscle contraction.  The myogenic mechanisms for decreased contraction 
include changes signaling pathways that lead to altered Ca
2+
 mobilization and MCL20 
phosphorylation (1-4, 13, 14, 31, 32, 34-37, 74-77, 93-96).  
Changes in Ca
2+
 mobilization.  Changes in Ca
2+
 mobilization is implicated in the 
dysmotility of colon from ulcerative colitis patients and in animal models of colitis (1-4, 35-37, 
39, 93-96).  Studies in both TNBS- and DSS-colitis have provided evidence for the decrease in 
voltage-dependent Ca
2+
 currents, and the decrease in Ca
2+
 currents has been attributed to either 
decrease in protein expression or altered regulation of the channel.  Decrease in expression was 
due to activation of transcription factor, NF-kB and altered regulation was due to inhibition of 
tyrosine phosphorylation by Src kinase (35-37, 85-86, 93, 96,).  In addition to the effect on Ca
2+
 
channels, inflammation enhances the ATP-sensitive K
+
 channels expression and currents (34).  
Decrease in Ca2+ currents and increase in K+ currents may act cooperatively to decrease smooth 
muscle contraction. In addition to Ca
2+
 and K+ channel functions, SERCA2 expression was 
reported to be decreased in colonic muscle during colitis, suggesting that reduced SR Ca
2+
 
uptake can also disrupt intracellular Ca
2+
 mobilization in smooth muscles from inflamed colon 
(4).  Studies on human colonic and esophageal sphincter smooth muscle suggest a role for 
endogenous H2O2 in the regulation of Ca
2+
 mobilization and SERCA2 activity in acute 
inflammation or upon exposure to IL-1 (13-14).  Studies also demonstrated that m3 receptor 
binding and Gq protein expression were not altered by exposure to IL-1, whereas PLC- 
activity was inhibited.  The inhibitory effect of IL-1β on PLC-β1 activity was attributed to up-
regulation of RGS4 (regulator of G protein signaling), since Gαq-GTP activity is rapidly 
terminated by RGS4. Inhibition of PLC-β1 activity leads to decrease in IP3 generation and IP3-
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dependent Ca
2+
 release.  Analysis of signaling pathways necessary for upregulation of RGS4 
suggests that colonic smooth muscle employ multiple signaling pathways such as PI3-
kinase/Akt, MAP kinases, and NF-kB, which is an immediate early nuclear transcription factor 
that is activated in response to proinflammatory cytokines (31-33).   
Changes in MLC20 phosphorylation. Previous studies also demonstrated that colonic 
inflammation impairs signal transduction pathways related to MLC20 phosphorylation.  Levels 
of MLC20 phosphorylation are regulated by the balance between MLCK activity and MLCP 
activity.  Phosphorylation of CPI-17, an endogenous inhibitor of MLCP, by PKC and MYPT1, a 
targeting subunit of MLCP, by Rho kinase in response to acetylcholine is essential for inhibition 
of MLC phosphatase and maintenance of sustained MLC20 phosphorylation and contraction.   
Both IL-1β and TNF-α down regulates expression of CPI-17, which leads to inhibition of 
MLC20 phosphorylation and contraction (31, 32, 74-77).  CPI-17 expression was also reduced in 
smooth muscle from patients with ulcerative colitis.  These studies suggest that CPI-17 down 
regulation might contribute to the decreased muscle contraction in inflammatory bowel diseases.  
The mechanisms involved in the down-regulation of CPI-17 remain unknown.   
As discussed in previous section, acto-myosin interaction and thus, muscle contraction are 
modulated the thin-filament associated proteins.  The involvement of molecular components of 
contractile apparatus, particularly thin-filament associated proteins in colonic inflammation has 
not been addressed.  Changes in the expression of caldesmon, calponin or tropomyosin that 
regulate the acto-myosin interaction could probably underlie the altered smooth muscle 
contraction.   
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It is our hypothesis that the expression of thin filament-associated proteins is altered 
during inflammation and contributes to the decreased contraction of colonic smooth muscle.   
The aim of the present study was to determine the changes in the expression of actin 
isoforms and actin-associated proteins such as caldesmon, calponin, tropomyosin, and 
smoothelin-A in colonic smooth muscle isolated from mouse colon following TNBS- and DSS-
induced colitis. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
1.   Materials 
1.1 Chemicals and antibodies.  Collagenase CLS type II and soybean trypsin inhibitor were 
obtained from Worthington, Freehold, NJ; Western blotting, and protein assay kit, Tris-HCl 
Ready Gels were obtained from Bio-Rad Laboratories, Hercules, CA; antibodies to α-actin, h-
caldesmon, h1-calponin, -tropomyosin, smoothelin-A were obtained from Santa Cruz 
biotechnology, Santa Cruz, CA; RNAqueous
TM
 kit was obtained from Ambion, Austin, TX; 
Effectene Transfection Reagent, QIAEX®II Gel extraction Kit and QIAprep®Spin Miniprep Kit 
were obtained from QIAGEN Sciences, Maryland; PCR reagents were obtained from Applied 
Biosystems, Roche. 2, 4, 6 trinitrobenzene sulphonic acid (TNBS) and all other chemicals were 
obtained from Sigma, St. Louis, MO. 
1.2 Animals.  C57BL/6J mice were obtained from Charles River and housed in pairs in 
microfilter-isolated cages for 7 days before use with access to food and water.  Animal care and 
treatment were conducted in accordance with the Institutional guidelines of the Virginia 
Commonwealth University.  Institutional Animal Care and Use Committee at the Virginia 
Commonwealth University approved all the experimental protocols.   
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2.   Methods 
2.1 Induction of colitis.  For TNBS-induced colitis, 6- to 8-weeks old male adult mice were 
fasted for 24 h before the induction of inflammation. Colonic inflammation was induced by 
intraluminal administration of single dose of TNBS (2.5% in 50% ethanol (v/v)). Mice were 
briefly anesthetized with isoflurane and 100 µl of TNBS solution was injected via a catheter 
advanced to 3 cm proximal to the anus via 1 ml syringe fitted with a catheter, and the mouse was 
kept in a vertical position with the head downwards for 1 min after the administration of the 
hapten, in order to distribute the agents within the entire colon.  Age-matched mice treated with 
vehicle only served as controls (57, 85, 86).  Each group of mice was euthanized 3 days after the 
induction of inflammation.  For DSS-induced colitis, 6- to 8-weeks old male adults were 
administered 5% w/v DSS (MW = 36 000–50 000 Da, MP Biomedicals LLC, Solon, OH, USA) 
ad libitum in the drinking water for 5 days (35).  All Mice were checked daily for loss of body 
weight, stool consistency and the presence of gross bleeding.  Colonic tissue from mice treated 
with TNBS or DSS exhibited typical histological characteristics of colitis (35, 57, 85, 86).   
2.2   Collection of tissue.   Mice were euthanized by CO2 inhalation followed by decapitation. 
Two- to three centimeter-long segments of the distal colon (starting from ~0.5 cm oral to the 
pelvic flexure) were obtained, immediately examined with the naked eye for macroscopic 
lesions, opened along the mesenteric border, cleaned, and pinned flat in a Petri dish with Sylgard 
base. The mucosal/submucosal layers were separated by microdissection. The muscularis 
propria, which included both the circular and longitudinal muscle layers were then quick frozen 
in liquid nitrogen and broken into small particles with a chilled pestle for protein and RNA 
extractions. The tissue particles were homogenized on ice in phosphate-buffered saline 
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supplemented with protease inhibitors for protein extraction.  For isolation of dispersed muscle 
cell, colon was emptied of its contents and placed in a cold smooth muscle buffer with the 
following composition: NaCl 120 mM, KCl 4 mM, KH2PO4 2.6 mM, CaCl2 2.0 mM, MgCl2 0.6 
mM, HEPES (N-2-hydroxyethylpiperazine-N’ 2-ethanesulfonic acid) 25 mM, glucose 14 mM, 
and essential amino mixture 2.1% (pH 7.4) (31, 32, 57). 
2.3   Preparation of dispersed colonic smooth muscle cells. Smooth muscle cells from colonic 
smooth muscle were isolated by sequential enzymatic digestion of muscle strips, filtration, and 
centrifugation as described previously (31, 32, 57, 70).  Colonic muscle were incubated for 20 
min in a smooth muscle buffer at 31C containing 0.1% collagenase (300 U/ml) and 0.01% 
soybean trypsin inhibitor (w/v). The tissue was continuously gassed with 100% oxygen during 
the entire isolation procedure.  The partly digested tissues were washed twice with 50-ml of 
collagenase-free smooth muscle buffer and the muscle cells were allowed to disperse 
spontaneously for 30 min in collagenase-free medium.  Cells were harvested by filtration through 
500 μm Nitex and centrifuged twice at 350 g for 10 min to eliminate broken cells and organelles. 
The cells were counted in a hemocytometer and it is estimated that 95% of the cells excluded 
trypan blue.  The experiments were done within 2-3 h of cell dispersion.  
 
2.4   Quantitative real-time RT-PCR analysis (qRT-PCR).  Total RNA was isolated from 
colonic muscle strips with TRIzol® reagent (Invitrogen) and then treated with TURBO DNase 
(Ambion).  RNA from each preparation was reversely transcribed using the SuperScript™ II 
system containing 50 mM Tris–HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol 
(DTT), 0.5 mM deoxynucleoside triphosphates (dNTP), 2.5 μM random hexamers and 200 units 
of reverse transcriptase in a 20 μl reaction volume. The reactions were carried out at room 
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temperature for 10 min and at 42°C for 50 min, and terminated by heating at 70°C for 15 min 
(31, 32, 57).  Quantitative RT-PCR was performed on cDNA samples using specific primers 
designed based on known sequences in mouse and TaqMan gene expression master mix.  The 
procedure is based on the time point during PCR cycling when amplification of PCR product is 
first detected rather than by the amount of PCR product accumulated after a fixed number of 
cycles.  The target gene copy number is quantified by measuring threshold cycle parameter (Ct), 
defined as fractional cycle at which the fluorescence generated by cleavage of probe passes a 
fixed threshold above the base line, and by using a standard curve to determine the starting copy 
number.   The primers are designed to satisfy the requirements for use of the 2
-ΔΔCT 
quantification 
method.  GAPDH expression was chosen to normalize the expression of the target genes. The 
GAPDH amplicon was utilized to normalize and calculate the quantitative expression of various 
genes. Thus, a quantitative comparison between samples from control and TNBS- or DSS-treated 
animal was calculated with the 2
-ΔΔCT 
method by normalizing the ΔCT counts to GAPDH 
expression.  Expression of the target gene mRNA was divided by the GAPDH mRNA.  Final 
results are expressed as fold difference in expression in TNBS- or DSS-treated samples relative 
to control samples.  All PCR reactions were performed in an ABI StepOne Plus PCR (Applied 
Biosystems, Foster City, CA).  PCR conditions were optimized on the gradient thermal cycler.  
For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume containing 
TaqMan gene Expression Master Mix (Applied Biosystems, Foster City, CA). The following 
time and temperature profile was used for the real-time PCR reactions:  95 ˚C for 5 min; 40 
cycles of a series consisting of 15 s at 94˚C, 30 s at 52˚C, 30 s at 72˚C; and a final extension of 5 
min at 72˚C. The optimal annealing temperatures were determined empirically for each primer 
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set. The sequences of specific primers are listed in the results section. The ABI sequence-
detection software and Microsoft Excel were used to calculate the quantities of the mRNAs.  
 
2.5    Western blot Analysis.  Frozen colonic tissues (100 mg) were pulverized while immersed 
in liquid nitrogen using a mortar. The muscle powder was collected into a glass tube and 
homogenized in buffer containing 20% glycerol, 50 mM tris-HCl (pH 6.8), 0.5% (volume per 
volume) Tween-20 and protease inhibitors (0.5 mM phenylmethanesulfonyl fluoride, 2 μM 
pepstatin, 2 μM antipain and 0.1 mg/ml trypsin inhibitor).  The homogenate was centrifuged 
(38,000 g) for 15 minutes using a Sorvall centrifuge and the supernatant was collected.  After 
gently mixing the samples in SDS (final concentration, 1%), they were boiled for 4 minutes and 
centrifuged at 10,000 rpm for 15 minutes. The supernatant was collected and the protein 
concentration was determined using the DC protein assay kit (BioRad Laboratories, Hercules, 
California).  Equal amounts (40 μg) of total protein from control and TNBS- and DSS-treated 
mice colonic muscle strips were loaded on 10% SDS-PAGE gels, using the buffer solution 
composed of 25 mM Tris, 192 mM glycine, 0.1% SDS and transferred to nitrocellulose 
membranes with Towbin buffer (25 mM tris, 192 mM glycine and 20% (v/v)) methanol.  
Membranes were subsequently blocked in blocking buffer (composition: 50 mM Tris·HCl, 150 
mM NaCl, 0.1% Tween 20, and 5% dried milk powder) for 90 min at room temperature. Next, 
membranes were incubated overnight at 4°C with primary antibodies [-actin (diluted 1:500), γ-
actin (diluted 1:1000), h-caldesmon (diluted 1:1000), h1-calponin (diluted 1:1000), -
tropomyosin (diluted 1:1000), and smoothelin-A (diluted 1:1000); all dilutions in blocking 
buffer].  After three washes with TBS-Tween 20 (0.1% TBST, containing 50 mM Tris·HCl, 150 
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mM NaCl, and 0.1% Tween 20) of 10 min each, membranes were incubated with horseradish 
peroxidase-labeled secondary antibodies (dilution 1:1000-3,000 in blocking buffer) at room 
temperature for 90 min, followed by an additional three washes with 0.1% TBST. Bands were 
subsequently visualized on film using SuperSignal Femto maximum sensitivity substrate kit 
(Pierce, USA) and analyzed by densitometry (31, 32, 70). All bands were normalized to β-actin 
expression. 
2.6   Immunohistochemistry.  Colonic tissue sections from control and TNBS-treated animals 
were processed for calponin, caldesmon, tropomyosin and smoothelin-A immunoreactivities 
using an on-slide immunostaining technique. After macroscopic observation, full thickness 
specimens from control and inflamed tissue and by immersion in 4% paraformadehyde, washed 
in PBS (3 × 10 min), cryoprotected in PBS-sucrose (30%), and embedded for cryostat sectioning 
in optimal cutting temperature compound. Cross sections (8-10μm) were cut and the slides 
containing the sections incubated for 1 h at room temperature with blocking solution containing 
5% normal donkey serum (Jackson ImmunoResearch, West Grove, PA) in PBST (0.3% Triton X-
100 in 0.1 M PBS, pH 7.4). The samples were then incubated in primary antibodies diluted in 
PBST containing 5% normal donkey serum overnight at 4 °C. The antibodies (Santa Cruz, CA) 
were used at 1:500 (caldesmon), 1:200 (calponin), 1:500 (tropomyosin) and 1: 500 (smoothelin) 
dilutions.   After rinsing (3 × 10 min with 0.1 M PBS), the tissue sections were incubated with 
fluorescence-conjugated species-specific secondary antibody Alexa 594 (1:200, Molecular 
Probes, Eugene, OR) for 2 h at room temperature. Following wash, the slides were coverslipped 
with Citifluor (Citifluor Ltd., London). Control sections incubated in the absence of primary or 
secondary antibody were also processed and evaluated for specificity or background staining 
levels. In the absence of primary antibody, no positive immunostaining for caldesmon, calponin, 
22 
 
tropomyosin and smoothelin was observed.  The specificity of primary antibodies was examined 
by western blot analysis. 
2.7    Measurement of contraction in dispersed smooth muscle cells. Contraction in freshly 
dispersed colonic smooth muscle cells was determined by scanning micrometry as previously 
described (32, 70).   An aliquot (0.4 ml) of cells containing approximately 10
4
 cells/ml was 
treated with 100 μl of medium containing different concentrations of acetylcholine (ACh; 10 pM 
to 1 µM) for 30 s and the reaction was terminated with 1% acrolein at a final concentration of 
0.1%.  Acrolein kills and fixes cells without affecting the cell length.   The resting cell length was 
determined in control experiments in which muscle cells were incubated with 100 l of 0.1% 
bovine serum albumin without the ACh.    The mean lengths of 50 muscle cells treated with 
various agonists was measured by scanning micrometry and compared with the mean lengths of 
untreated cells. The contractile response was expressed as the percent decrease in mean cell 
length from control cell length.   
 
3.  STATISTICAL ANALYSIS  
 
The results were expressed as means  SE of n experiments and analyzed for statistical 
significance using Student’s t-test for paired and unpaired values.  Each experiment was done on 
cells obtained from different animals.  Five mice of each group were studied; qRT-PCR and 
western blot were performed in duplicate.  Differences among multiple groups were tested by 
using ANOVA and checked for significance using Fisher's protected least significant difference 
test. A probability of p < 0.05 was considered significant.   
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Table 1. RT-PCR TaqMan primers for the amplification of thin-filaments associated 
proteins 
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Table 1 
 
 
 
 
 
 
 
Product size Company name Aaaay ID Primer set 
59 bp Applied Biosystems Mm00487032- m1 Cnn1 
102 bp Applied Biosystems Mm00513995- m1 Cald1 
97 bp Applied Biosystems Mm00437172- g1 Tpm2 
66 bp Applied Biosystems Mm00449973- m1 Smtn 
107 bp Applied Biosystems NM-008084.2 GAPDH 
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Table 2. RT-PCR SYBRgreen primers for the amplification of thin-filaments associated 
proteins 
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Table 2 
 
 
 
 
 
 
Product 
size 
Reverse 3'5' Forward 5'3' Primer 
set 
103 bp CGAAGCCGGCCTTACAGA CGCTGTCAGGAACCCTGAGA α-actin 
60 bp GGTACGGCCGGATGCAT GTCCCTGCCATGTATGTTGCTA γ-actin 
99 bp GCTTGGGATCCACACTCTCCAGCT TACCTGTGGCCTTGGGCCTCAA IL-1B 
81 bp TTGGTGGTTTGCTACGACGTGGG ATGGCCCAGACCCTCACACTCAG TNF-α 
122 bp GGAGTTGCTGTTGAAGTCG AGAAACCTGCCAAGTATGATG GAPDH 
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Table 3. Western blot antibodies for thin-filaments associated proteins 
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Table 3 
 
 
 
Dilution Company 
name 
Product size 
(kDa) 
Catalog# Antibody 
1/1000 
SANTA CRUZ 
33-36 Sc-58707 Calponin 1 
(CALP) 
1/1000 
SANTA CRUZ 
90-150 sc-15374 Caldesmon 
 (H-300) 
1/1000 
SANTA CRUZ 
35-45 sc-28543 Tropomyosin 
 (FL-284) 
1/1000 
SANTA CRUZ 
115 Sc-20481 Smoothelin 
(C-20) 
1/1000 
MILLIPORE 
43 Clone E184 Alpha-actin 
1/1000 CHEMICON 
TEMECULA 
42 AB 3265  Gamma-actin 
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CHAPTER 3: RESULTS 
 
 
 
In the present study, we analyzed the changes in the expression of α-actin, γ-actin, 
caldesmon, calponin, tropomyosin and smoothelin-A in smooth muscle of colon isolated from 
control mice and TNBS- and DSS-induced colitic mice by qRT-PCR and Western blot.   
For q-RT-PCR specific primers were designed based on known sequences in mouse 
(Table 1and 2).  The accuracy of the designed primers was evaluated with gel-electrophoresis.  
Melt curve analyses showed single peaks for all samples. The PCR efficiencies were calculated 
from standard curves.  These findings validated the design of primers and satisfied the 
requirements for use of the 2
-ΔΔCT 
quantification method, described previously in the Materials 
and Methods section.  GAPDH expression was chosen to normalize the expression of the 
contractile proteins. The GAPDH amplicon was utilized to normalize and calculate the 
quantitative expression of various genes. Thus, a quantitative comparison between inflamed and 
normal tissue was calculated with the 2
-ΔΔCT 
method by normalizing the ΔCT counts to GAPDH 
expression.  
For western blot analysis equal amounts of protein were subjected to electrophoresis and 
transferred to nitrocellulose or polyvinylidene difluoride membranes. Membranes were incubated 
with antibodies to α-actin, γ-actin, h-caldesmon, calponin, tropomyosin or smoothelin-A with 
appropriate dilutions (Table 3).  Following ECL protocol as described in the Methods, protein 
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bands of the expected size were analyzed by densitometry and all bands normalized to β-actin 
expression. 
For immunohistochemistry tissue sections were incubated in primary antibodies followed 
by fluorescence-conjugated species-specific secondary antibody. Control sections incubated in 
the absence of primary or secondary antibody showed no positive staining.  The specificity of 
antibodies used was confirmed by western blot analysis. 
3.1   Evaluation of colonic inflammation 
Macroscopic examination of the distal colon rectum 5days after TNBS administration 
revealed multiple mucosal erosions and ulceration which were in sharp contrast with the 
appearance of the normal colon excised from control animals with intact smooth mucosa.  IL-1β, 
as a vital proinflammatory cytokine, plays an important role in colitis (86, 93, 97).  The release 
of this cytokine in turn increases the expression of other cytokines and positively contributes to 
the progress of inflammatory bowel disease and experimental colitis in animal models of 
inflammatory bowel disease.  Previous studies demonstrated that IL-1β or TNF-α acting on 
muscle cells alters the expression of signaling proteins involved in the regulation of contraction 
(31, 32, 93).  Therefore, we tested whether the expression of IL-1β increases in smooth muscle 
tissue during TNBS- and DSS-induced colitis.   Expression of IL-1β and TNF-α was measured 
by qRT-PCR using specific primers (IL-1 β: forward primer, 
TACCTGTGGCCTTGGGCCTCAA; reverse primer, GCTTGGGATCCACACTCTCCAGCT 
and TNF-α forward primer, ATGGCCCAGACCCTCACACTCAG; reverse primer, 
TTGGTGGTTTGCTACGACGTGGG).  Indeed, the expression of both IL-1β and TNF-α was 
significantly increased (IL-β: 10-fold and 75-fold with TNBS and DSS, respectively, and TNF-α: 
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3-fold and 4-fold with TNBS and DSS, respectively, p<0.05, n=3-5) in inflammatory colonic 
tissue in colitis compared to control tissue (Figs. 1 and 2).  These results strongly suggested that 
TNBS-treatment results in the generation of proinflammatory cytokines. 
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Figure 1.  Expression of IL-1β in the colonic muscle after TNBS or DSS treatment.  Total 
RNA isolated from smooth muscle strips of control and TNBS or DSS treated mice using 
RNAqueous prep kits (Ambion, Austin, Tx) and was reverse transcribed using 2 µg of total RNA 
using qScript cDNA prep kits (Quanta, Gaithersburg, MD).  The cDNA was amplified with 
specific primers for IL-1β.  The sequences of specific primers are listed in Table 1.  Quantitative 
real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels of IL-1β.  For 
each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume containing 
Quantitect
TM 
SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON).  Real-time PCR reactions 
were performed in triplicate.   Results are expressed as fold differences in IL-1β gene expression 
in TNBS- or DSS-treated colon relative to that in vehicle-treated colon. Values represent the 
means SEM of 5 separate experiments.  **p<0.001 versus control.
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                                                                                                                                 Figure 1 
 
 
34 
 
Figure 2.  Expression of TNF-α in the colonic muscle after TNBS or DSS treatment.  Total 
RNA isolated from smooth muscle strips of control and TNBS or DSS treated mice using 
RNAqueous prep kits (Ambion, Austin, Tx) and was reverse transcribed using 2 µg of total RNA 
using qScript cDNA prep kits (Quanta, Gaithersburg, MD).  The cDNA was amplified with 
specific primers for TNF-α.  Quantitative real-time polymerase chain reaction (qRT-PCR) was 
used to measure RNA levels of TNF-α.  For each cDNA sample, real-time PCR was conducted 
in a 20-μl reaction volume containing Quantitect
TM 
SYBRgreen PCR Mastermix (Qiagen, 
Mississauga, ON).  Real-time PCR reactions were performed in triplicate.   Results are expressed 
as fold differences in TNF-α gene expression in TNBS- or DSS-treated colon relative to that in 
vehicle-treated colon. Values represent the means SEM of 3 separate experiments.  **p<0.05 
versus control. 
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Figure 2
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3.2     Changes in the expression of thin-filament associated proteins in TNBS-colitis mice.   
3.2.1 Actins.   Six actin isoforms (α-skeletal, α-cardiac, and α-vascular; γ-enteric and γ-
cytoplasmic; and β-cytoplasmic) have been described and are products of separate genes (28, 
67). The α-vascular and γ-enteric actin isoforms are smooth muscle specific and associated with 
the contractile proteins, whereas β- and γ-cytoplasmic actins are non-muscle isoforms and 
associated with non-contractile cytoskeleton.  Expression of - and -actin was measured in 
colonic muscle of control and TNBS-colitic mice.  The differences in the expression levels were 
analyzed by qRT-PCR using specific primers (-actin: forward primer, 
CGCTGTCAGGAACCCTGAGA; reverse primer, CGAAGCCGGCCTTACAGA and γ-actin: 
forward primer, GTCCCTGCCATGTATGTTGCTA; reverse primer, 
GGTACGGCCGGATGCAT).  The results showed that expression of α-actin and -actin was 2-
fold higher (p<0.05, n=5) in colonic muscle cells from TNBS mice compared to control mice 
(Figs. 3 and 4).  Protein expression of α-actin protein was examined by western blot analysis 
using an antibody that recognizes selectively α-actin.  Results showed expression of one protein 
band with ~45kDa and the molecular weight of the protein band corresponds to the expected 
molecular weight of α-actin isoform (42 kDa).  Comparing the densities of protein bands 
revealed 3-fold higher expression in muscle from TNBS mice compared to control mice (Fig. 3) 
(p<0.05).  α-actin immunoreactivity was also observed from colonic tissue sections of both 
control and TNBS-treated mice and the immunoreactivity was predominant in muscularis propria 
and intensity of immunoreactivity appears to be greater in tissues from TNBS mice compared to 
control mice (Fig. 3) 
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3.2.2. Caldesmon.   Two caldesmon isoforms (h-caldesmon and l-caldesmon) have been 
described.  The h-caldesmon is smooth muscle specific, whereas l-caldesmon is non-muscle 
isofrom (6).  Expression of h-caldesmon was measured in colonic muscle of control and TNBS-
colitic mice.  The differences in the expression levels were analyzed by qRT-PCR using specific 
primers (assay ID: Mm00513995- m1, Applied Biosystems).  The results showed that expression 
of h-caldesmon was 7-fold higher (p<0.001) in colonic muscle cells from TNBS mice compared 
to control mice (Fig. 5).  Protein expression of h-caldesmon was examined by western blot 
analysis using an antibody that recognizes selectively h-caldesmon.  Results showed expression 
of one protein band with ~100 kDa and the molecular weight of the protein band corresponds to 
the expected molecular weight of h-caldesmon isoform.  Comparing the densities of protein 
revealed 2.5-fold higher (p<0.05) expression in muscle from TNBS mice compared to control 
mice (Fig. 5).  h-caldesmon immunoreactivity was observed from colonic tissue sections of both 
control and TNBS-treated mice and the immunoreactivity was predominant in muscularis propria 
and intensity of immunoreactivity appears to be greater in tissues from TNBS mice compared to 
control mice (Fig. 5).  
 
3.2.3. Calponin.   Three calponin isoforms (h1-acidic, h2-neutral and basic calponin) 
have been described.  The h2-acidic is smooth muscle specific, whereas h2-neutral and basic 
calponin are non-muscle isoforms (12).  Expression of h2-calponin was measured in colonic 
muscle of control and TNBS-colitic mice.  The differences in the expression levels were 
analyzed by qRT-PCR using specific primers (assay ID: Mm00487032-m1, Applied 
Biosystems).  The results showed that expression of h2-calponin was ~4-fold higher (p<0.001) in 
colonic muscle cells from TNBS mice compared to control mice (Fig. 6).  Protein expression of 
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h-calponin also examined by western blot analysis using an antibody that recognizes selectively 
h2-calponin.  Results showed expression of one protein band with 35 kDa and the molecular 
weight of the protein band corresponds to the expected molecular weight of h2-calponin 
isoforms.   Comparing the densities of protein revealed 3-fold higher (p<0.001) expression in 
muscle from TNBS mice compared to control mice (Fig. 6).  h1-calponin immunoreactivity was 
observed from colonic tissue sections of both control and TNBS-treated mice and the 
immunoreactivity was predominant in muscularis propria and intensity of immunoreactivity 
appears to be greater in tissues from TNBS mice compared to control mice (Fig. 6). 
  
3.2.4. Tropomyosin.   Two tropomyosin isoforms (α- and β-tropomyosin) have been 
described (28, 67).    Expression of α-tropomyosin was measured in colonic muscle of control 
and TNBS-colitic mice.  The differences in the expression levels were analyzed by qRT-PCR 
using specific primer (assay ID: Mm00437172-g1, Applied Biosystems).  The results showed 
that expression of α-tropomyosin was 2-fold higher in colonic muscle cells from TNBS mice 
compared to control mice (Fig. 7).  Protein expression of α-tropomyosin was examined by 
western blot analysis using an antibody that recognizes both isoforms.  Results showed 
expression of one protein band with ~35 kDa and the molecular weight of the protein band 
corresponds to the expected molecular weight of α-tropomyosin.  Comparing the densities of 
protein revealed a 2.5-fold higher (p<0.05) expression in muscle from TNBS mice compared to 
control mice (Fig. 7). Α tropomyosin immunoreactivity was also observed from colonic tissue 
sections of both control and TNBS-treated mice and the immunoreactivity was predominant in 
muscularis propria and intensity of immunoreactivity appear to be greater in tissues from TNBS 
mice compared to control mice (Fig. 7). 
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3.2.5. Smoothelin.   Two smoothelin isoforms (Smoothelin-A and -B) have been 
described.    Expression of smoothelin-A is specific to visceral smooth muscle, whereas 
smoothelin-B is specific to vascular smooth muscle (72, 84).  Smoothelin-A was measured in 
colonic muscle of control and TNBS-colitic mice.  The differences in the expression levels were 
analyzed by qRT-PCR using specific primers (assay ID: Mm00449973-m1, Applied 
Biosystems).  The results showed that expression of smoothelin-A was 2-fold greater in colonic 
muscle cells from TNBS mice compared to control mice (Fig. 8).  Protein expression of 
smoothelin-A was also examined by western blot analysis using an antibody that recognizes both 
isoforms.  Results showed expression of one protein band with 60 kDa and the molecular weight 
of the protein band corresponds to the expected molecular weight of smoothelin-A.  Comparing 
the densities of protein revealed 2-fold higher expression in muscle from TNBS mice compared 
to control mice (Fig. 8).  Smoothelin-A immunoreactivity was observed from colonic tissue 
sections of both control and TNBS-treated mice and the immunoreactivity was predominant in 
muscularis propria and intensity of immunoreactivity appears to be greater in tissues from TNBS 
mice compared to control mice (Fig. 8)  
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Figure 3.  Expression of -actin in the colonic muscle after TNBS treatment.  (A) mRNA 
expression.  Total RNA isolated from smooth muscle strips of control and TNBS treated mice 
using RNAqueous prep kits (Ambion, Austin, Tx) and was reverse transcribed using 2 µg of total 
RNA using qScript cDNA prep kits (Quanta, Gaithersburg, MD).  The cDNA was amplified with 
specific primers for -actin.  Quantitative real-time polymerase chain reaction (qRT-PCR) was 
used measure RNA levels of -actin.  For each cDNA sample, real-time PCR was conducted in a 
20-μl reaction volume containing Quantitect
TM 
SYBRgreen PCR Mastermix (Qiagen, 
Mississauga, ON).  Real-time PCR reactions were performed in triplicate.   Results are expressed 
as fold differences in -actin gene expression in TNBS-treated colon relative to that in control 
colon. Values represent the means SEM of 5 separate experiments.  *p<0.05 versus control. (B) 
Protein expression.  Colonic muscle tissue lysates containing equal amounts of total proteins 
were separated with SDS-PAGE and expression of -actin was analyzed using selective 
antibody. Results are expressed as fold differences in -actin protein expression in TNBS-treated 
colon relative to that in vehicle-treated colon. Values represent the means SEM of 5 separate 
experiments.  *p<0.05 versus control.  (C) Immunohistochemistry.  Representative 
photomicrographs for -actin staining in control and TNBS-treated colon.  Note increase in the 
staining for -actin in tissue sections from TNBS-treated animals.  
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Figure 4.  Expression of γ-actin in the colonic muscle after TNBS treatment.   Total RNA 
isolated from smooth muscle strips of control and TNBS treated mice using RNAqueous prep 
kits and was reverse transcribed using 2 µg of total RNA.  The cDNA was amplified with 
specific primers for γ-actin.  Quantitative real-time polymerase chain reaction (qRT-PCR) was 
used measure RNA levels of γ-actin.  For each cDNA sample, real-time PCR was conducted in a 
20-μl reaction volume containing Quantitect
TM 
SYBRgreen PCR Mastermix.  Real-time PCR 
reactions were performed in triplicate.   Results are expressed as fold differences in γ-actin gene 
expression in TNBS-treated colon relative to that in control colon. Values represent the means 
SEM of 5 separate experiments.  
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Figure 5.  Expression of h-caldesmon in the colonic muscle after TNBS treatment.  (A) 
mRNA expression.  Total RNA isolated from smooth muscle strips of control and TNBS treated 
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using 
qScript cDNA prep kits.  The cDNA was amplified with specific primers for h-caldesmon.  
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of 
h-caldesmon.  For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume 
containing Quantitect
TM 
TaqMan PCR Mastermix.  Real-time PCR reactions were performed in 
triplicate.   Results are expressed as fold differences in h-caldesmon gene expression in TNBS-
treated colon relative to that in control colon. Values represent the means SEM of 5 separate 
experiments.  **p<0.001 versus control. (B) Protein expression.  Colonic muscle tissue lysates 
containing equal amounts of total proteins were separated with SDS-PAGE and expression of h-
caldesmon was analyzed using selective antibody. Results are expressed as fold differences in h-
caldesmon protein expression in TNBS-treated colon relative to that in control colon. Values 
represent the means SEM of 5 separate experiments.  *p<0.05 versus control.  (C) 
Immunohistochemistry.  Representative photomicrographs for h-caldesmon staining in control 
and TNBS-treated colon.  Note increase in the staining for h-caldesmon in tissue sections from 
TNBS-treated animals. 
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Figure 6.  Expression of h1-calponin in the colonic muscle after TNBS treatment.  (A) 
mRNA expression.  Total RNA isolated from smooth muscle strips of control and TNBS treated 
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using 
qScript cDNA prep kits.  The cDNA was amplified with specific primers for h1-calponin.  
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of 
h1-calponin.  For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume 
containing Quantitect
TM 
TaqMan PCR Mastermix.  Real-time PCR reactions were performed in 
triplicate.   Results are expressed as fold differences in h1-calponin gene expression in TNBS-
treated colon relative to that in control colon. Values represent the means SEM of 5 separate 
experiments.  **p<0.05 versus control. (B) Protein expression.  Colonic muscle tissue lysates 
containing equal amounts of total proteins were separated with SDS-PAGE and expression of 
h1-calponin was analyzed using selective antibody. Results are expressed as fold differences in 
h1-calponin protein expression in TNBS-treated colon relative to that in control colon. Values 
represent the means SEM of 5 separate experiments.  **p<0.001 versus control.  (C) 
Immunohistochemistry.  Representative photomicrographs for h1-calponin staining in control 
and TNBS-treated colon.  Note increase in the staining for h-calponin in tissue sections from 
TNBS-treated animals. Scale bar = 200 μm. 
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Figure 7.  Expression of -tropomyosin in the colonic muscle after TNBS treatment.  (A) 
mRNA expression.  Total RNA isolated from smooth muscle strips of control and TNBS treated 
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using 
qScript cDNA prep kits.  The cDNA was amplified with specific primers for -tropomyosin.   
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of 
-tropomyosin.  For each cDNA sample, real-time PCR was conducted in a 20-μl reaction 
volume containing Quantitect
TM 
TaqMan PCR Mastermix.  Real-time PCR reactions were 
performed in triplicate.   Results are expressed as fold differences in -tropomyosin gene 
expression in TNBS-treated colon relative to that in control colon. Values represent the means 
SEM of 5 separate experiments.  *p<0.05 versus control. (B) Protein expression.  Colonic 
muscle tissue lysates containing equal amounts of total proteins were separated with SDS-PAGE 
and expression of -tropomyosin was analyzed using selective antibody. Results are expressed 
as fold differences in -tropomyosin protein expression in TNBS-treated colon relative to that in 
control colon. Values represent the means SEM of 5 separate experiments.  *p<0.05 versus 
control.  (C) Immunohistochemistry.  Representative photomicrographs for -tropomyosin 
staining in control and TNBS-treated colon.  Note increase in the staining for h-calponin in tissue 
sections from TNBS-treated animals.  
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Figure 8.  Expression of smoothelin-A in the colonic muscle after TNBS treatment.  (A) 
mRNA expression.  Total RNA isolated from smooth muscle strips of control and TNBS treated 
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using 
qScript cDNA prep kits.  The cDNA was amplified with specific primers for smoothelin-A.   
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of 
smoothelin-A.  For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume 
containing Quantitect
TM 
TaqMan PCR Mastermix.  Real-time PCR reactions were performed in 
triplicate.   Results are expressed as fold differences in smoothelin-A gene expression in TNBS-
treated colon relative to that in control colon. Values represent the means SEM of 5 separate 
experiments. (B) Protein expression.  Colonic muscle tissue lysates containing equal amounts of 
total proteins were separated with SDS-PAGE and expression of smoothelin-A was analyzed 
using selective antibody. Results are expressed as fold differences in smoothelin-A protein 
expression in TNBS-treated colon relative to that in control colon. Values represent the means 
SEM of 5 separate experiments.  (C) Immunohistochemistry.  Representative 
photomicrographs for smoothelin-A staining in control and TNBS-treated colon.  Note increase 
in the staining for h-calponin in tissue sections from TNBS-treated animals. 
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Figure: 8 
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3.3. Changes in the expression of thin-filament associated proteins in DSS-colitis mice.   
To determine whether the up-regulation of thin filament associated proteins observed in 
the colonic muscle of TNBS-induced colitis is also observed in an another model of colitis, mice 
were treated with DSS for 5 days and the expression of caldesmon, calponin, tropomyosin and 
smoothelin-A were analyzed by qRT-PCR and western blot in colonic smooth muscle isolated 
from control and DSS-treated mice.  Analysis of mRNA and proteins expression results revealed 
higher expression of calponin (~2-fold, Fig. 10), caldesmon (3- to 4-fold; p<0.001, Fig. 9), 
tropomyosin (2-3-fold, Fig. 11), and smoothelin-A (~2-fold, Fig. 12) in colonic muscle cells 
from DSS mice compared to control mice.  These results suggest that inflammation induced by 
either TNBS or DSS treatment had similar effect on the expression thin-filament associated 
proteins.   
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Figure 9.  Expression of h-caldesmon in the colonic muscle after DSS treatment.  (A) mRNA 
expression.  Total RNA isolated from smooth muscle strips of control and DSS treated mice 
using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using qScript 
cDNA prep kits.  The cDNA was amplified with specific primers for h-caldesmon.  Quantitative 
real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of h-
caldesmon.  For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume 
containing Quantitect
TM 
TaqMan PCR Mastermix.  Real-time PCR reactions were performed in 
triplicate.   Results are expressed as fold differences in h-caldesmon gene expression in DSS-
treated colon relative to that in control colon. Values represent the means SEM of 5 separate 
experiments.  **p<0.05 versus control.  (B) Protein expression.  Colonic muscle tissue lysates 
containing equal amounts of total proteins were separated with SDS-PAGE and expression of h-
caldesmon was analyzed using selective antibody. Results are expressed as fold differences in h-
caldesmon protein expression in DSS-treated colon relative to that in control colon. Values 
represent the means SEM of 5 separate experiments.   **p<0.05 versus control.   
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Figure: 9 
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Figure 10.  Expression of h1-calponin in the colonic muscle after DSS treatment.  (A) 
mRNA expression.  Total RNA isolated from smooth muscle strips of control and DSS treated 
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using 
qScript cDNA prep kits.  The cDNA was amplified with specific primers for h1-calponin.    
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of 
h1-calponin.  For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume 
containing Quantitect
TM 
TaqMan PCR Mastermix.  Real-time PCR reactions were performed in 
triplicate.   Results are expressed as fold differences in h1-calponin gene expression in DSS-
treated colon relative to that in control colon. Values represent the means SEM of 5 separate 
experiments.  *p<0.05 versus control. (B) Protein expression.  Colonic muscle tissue lysates 
containing equal amounts of total proteins were separated with SDS-PAGE and expression of 
h1-calponin was analyzed using selective antibody. Results are expressed as fold differences in 
h1-calponin protein expression in DSS-treated colon relative to that in control colon. Values 
represent the means SEM of 5 separate experiments.  *p<0.05 versus control. 
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Figure 11.  Expression of -tropomyosin in the colonic muscle after DSS treatment.  (A) 
mRNA expression.  Total RNA isolated from smooth muscle strips of control and DSS treated 
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using 
qScript cDNA prep kits.  The cDNA was amplified with specific primers for -tropomyosin.  
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of 
-tropomyosin.  For each cDNA sample, real-time PCR was conducted in a 20-μl reaction 
volume containing Quantitect
TM 
TaqMan PCR Mastermix.  Real-time PCR reactions were 
performed in triplicate.   Results are expressed as fold differences in -tropomyosin gene 
expression in DSS-treated colon relative to that in control colon. Values represent the means 
SEM of 5 separate experiments.  *p<0.05 versus control. (B) Protein expression.  Colonic 
muscle tissue lysates containing equal amounts of total proteins were separated with SDS-PAGE 
and expression of -tropomyosin was analyzed using selective antibody. Results are expressed 
as fold differences in -tropomyosin protein expression in DSS-treated colon relative to that in 
control colon. Values represent the means SEM of 5 separate experiments.  *p<0.05 versus 
control.   
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Figure 12.  Expression of smoothelin-A in the colonic muscle after DSS treatment.  (A) 
mRNA expression.  Total RNA isolated from smooth muscle strips of control and DSS treated 
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using 
qScript cDNA prep kits.  The cDNA was amplified with specific primers for smoothelin-A.   
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of 
smoothelin-A.  For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume 
containing Quantitect
TM 
TaqMan PCR Mastermix.  Real-time PCR reactions were performed in 
triplicate.   Results are expressed as fold differences in smoothelin-A gene expression in DSS-
treated colon relative to that in control colon. Values represent the means SEM of 5 separate 
experiments.  (B) Protein expression.  Colonic muscle tissue lysates containing equal amounts 
of total proteins were separated with SDS-PAGE and expression of smoothelin-A was analyzed 
using selective antibody. Results are expressed as fold differences in smoothelin-A protein 
expression in DSS-treated colon relative to that in control colon. Values represent the means 
SEM of 5 separate experiments.  *p<0.05 versus control.  
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3.4. Effect of inflammation on muscle contraction.  
To determine whether changes in the expression of thin-filament proteins was associated 
with changes in agonist-induced contraction, freshly dispersed colonic muscle cells from control 
mice and TNBS-colitis mice were treated with different concentrations of acetylcholine and 
decrease in muscle cell length was measured by scanning micrometry.  Basal muscle cell lengths 
were similar in control (954 m) and TNBS-colitis (915 m) and ACh caused contraction that 
was concentration-dependent in muscle cells from both control and TNBS-colitis mice (Fig. 13).  
However contraction in response to ACh was significantly lower in TNBS-colitis mice compared 
to control mice.  The maximal response to 0.1 M ACh was also significantly lower in TNBS-
colitis mice (322% decrease in cell length) compared to control mice (203% decrease in cell 
length) (Fig. 13).  These results are consistent with the previous studies in several animal models 
of inflammation.   
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Figure 13.  Effect of TNBS treatment on ACh-induced muscle contraction.  Contraction of 
dispersed muscle cells from colon was measured by scanning micrometry in response to different 
concentrations of ACh.  Cells were treated with ACh for 30s and contraction was expressed as 
percent decrease in cell length from basal cell length: basal length of muscle cells from control 
mice 1254 µm; basal control length of muscle cells from TNBS-colitis mice 1185 µm.  ACh 
caused contraction that was concentration-dependent in both inflamed and control. Contraction 
was significantly attenuated in cells from TNBS-colitis mice.  The maximal response to 0.1 µM 
of ACh was 322% decrease in cell length in control mice and 203% decrease in cell length in 
TNBS-colitis mice. Values represent the means SEM of 5 separate experiments.  **p<0.05 
significant inhibition of contraction compared to control mice. 
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CHAPTER 4: DISCUSSION 
 
 
 
Altered motility is induced by colonic inflammation, and this abnormality may lead to the 
diarrhea or constipation characteristic of IBD.  It has been suggested that many factors, including 
changes in the function of ENS, ICC and smooth muscle are associated with altered colonic 
motility (1-4, 17-22, 25, 35-37, 63, 82, 93-96).   The smooth muscle cells of the gastrointestinal 
tract are the final effectors of force development and work, and thus, it is important to understand 
the changes in expression of contractile proteins, which constitutes the main contractile 
apparatus of smooth muscle.  In the present study, we examined the effects of colonic 
inflammation on the contractile properties of colonic smooth muscle by two well-characterized 
animal models of colitis such as TNBS (hapten)- and DSS-induced mouse models and three 
different approaches to measure the changes in the expression such as qRT-PCR, western blot 
and immunohistochemistry. Biochemically, the colonic inflammation induced by TNBS or DSS 
was characterized by an increased IL-1β expression, which is indicative of inflammation that 
occurs in these animal models of colitis, as well as in human IBD (7, 56). 
Our main findings are: 1) expression of thin filament proteins involved in acto-myosin 
interaction and contraction such as α-actin, γ-actin is increased, 2) expression of thin-filament 
associated proteins involved in the regulation of acto-myosin interaction and contraction such as 
tropomyosin, smoothelin, calponin and caldesmon is increased, 3) contraction induced by 
acetylcholine in isolated smooth muscle cells is decreased by colitis, 4) The changes in the 
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expression of contractile proteins is observed at both protein and mRNA levels and the extent of 
changes in the expression of contractile proteins is similar in both TNBS- and DSS-induced 
colitic models.  The present investigation of the response of the contractile proteins to 
inflammation may provide further insights into the mechanism by which inflammation modifies 
contractile proteins and suggests that inflammation may contribute to the regulation of the 
expression of genes responsible for synthesis of smooth muscle contraction proteins.  Chronic 
inflammation of the colon also induces both hyperplasia and hypertrophy of the muscle leading 
to alterations in the cellular architecture (57).  Increase in the expression of contractile proteins, 
major components of both contractile apparatus and the cytoskeletal structure of smooth muscle 
could contribute to the inflammation-induced changes in smooth muscle cellular architecture.  
Although TNBS and DSS are shown to mediate inflammation via distinct inflammatory 
mediators, several studies demonstrated similar decrease in spontaneous and agonist-mediated 
colonic muscle contraction in both models (16, 27, 40-49, 79, 90).  In addition, alterations in 
Ca
2+
 handling and signal transduction pathway involved in muscle contraction are similar in both 
models (1-4, 13, 14, 34-37, 74-77, 93-96).    
Contraction of smooth muscle is determined by the stimulation of ATPase activity of the myosin 
II, the main molecular motor for contraction, upon its interaction with actin.  Stimulation of 
ATPase activity is greatly facilitated by the phosphorylation of 20-kDa myosin light chains 
(MLC20) by MLC kinase (28, 29, 38, 67, 69, 81, 89-91).  A high correlation between MLC20 
phosphorylation and muscle contraction has been demonstrated previously.  The levels of 
MLC20 phosphorylation are regulated by opposing activities of MLC kinase and MLC 
phosphatase, whose activities, in turn, are regulated by feedback mechanism such as inhibition of 
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MLCK via CaMKII or AMP kinase, and activation or inhibition MLCP via telokin and CPI-17, 
respectively (38, 69, 89, 90).  Previous studies have demonstrated that either exposure of 
cultured muscle cells in vitro to IL-1β or TNF-α or during inflammation in vivo has specific 
effects on the expression and activity of various targets in the signaling pathways mediating 
contraction and relaxation (14, 31, 32, 93-96).  Colonic inflammation induced by TNBS or DSS 
also alters expression and/or activity of Ca2+ channels, K
+
 channels and SERCA2 suggesting an 
imbalance in Ca2+ mobilization mechanisms (1-4, 35-7, 39, 85-86, 94).   
Contraction of smooth muscle is determined by mechanisms that regulate the availability of actin 
to interact with myosin via the action of inhibitory actin binding proteins such as caldesmon and 
calponin (6, 12, 28, 67).  These thin-filament associated proteins are capable of stabilizing actin 
filaments.  Caldesmon is a highly conserved, actin and myosin binding protein and exists in two 
isoforms: expression of heavy isoform (h-caldesmon) is specific to smooth muscle cells, whereas 
light isoform (l-caldesmon) is expressed in both non-muscle and dedifferentiated smooth muscle 
cells. Caldesmon inhibits acto-myosin interaction and the inhibitory is reversed by binding of 
Ca2+/CaM or by phosphorylation via ERK1/2 (6, 28, 67).  Calponin is an actin binding protein 
and exists in three isoforms: expression of h1 calponin (basic calponin) is specific to smooth 
muscle, whereas h2 calponin (neutral calponin) and acidic non-muscle. Calponin inhibits acto-
myosin ATPase activity interaction and the inhibition is reversed by phosphorylation via ERK1/2 
or PKC. Thus caldesmon and calponin are important regulators of smooth muscle contraction 
(12, 28, 67).  Although studies suggest that tropomyosin is necessary for full inhibition of acto-
myosin activity by caldesmon, the exact mechanism of action is unclear (28, 67).   The data 
presented in the current study reveal an association between increases in the expression of thin-
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filament associated proteins, especially, caldesmon, calponin and tropomyosin in response to 
inflammation and decreased muscle contraction. Caldesmon and calponin inhibit muscle 
contraction and actin-activated ATPase activity, and tropomyosin enhances the caldesmon-
induced inhibition of actomyosin ATPase.  The low force in the presence of high levels of 
MLC20 phosphorylation was attributed to the suppression of acto-myosin ATPase activity and 
force generation by the high levels of caldesmon and calponin. The cytoskeleton modifications 
due to increased expression of thin-filament associated proteins may also have an effect on 
smooth muscle contraction.  However, evidence for the cytoskeleton remodeling on cell 
contraction is lacking.  Thus, our study in combination with previous studies proposes that in 
colitis, several mechanisms result in attenuated muscle contraction.  First, a lower expression 
and/or activity of L-type Ca2+ channels result in decrease in intracellular Ca2+ and inhibition of 
Ca2+/CaM-dependent MLCK activity (1-4, 35-37, 96).  Second, a lower expression of CPI-17, 
an endogenous inhibition of MLCP, results in stimulation of MLCP activity (31, 74-76).  Third, 
a greater expression of caldesmon and calponin results in attenuation of acto-myosin interaction.  
Further investigations might reveal whether the proposed mechanisms are dependent on each 
other or occur independently, and whether a singular mechanism is sufficient to produce altered 
muscle contraction.  Smoothelin is an actin binding protein and exists in two isoforms: 
expression of smoothelin-A is selective to visceral smooth muscle, whereas expression of 
smoothelin-B is selective to vascular smooth muscle.  Expression of both isoforms is abundant in 
contractile smooth muscle cells and limited in non-contractile proliferative smooth muscle cells.  
Recent studies using transgenic mice suggest expression of smoothelin-A is important slow wave 
activity and agonist-mediated contraction of gastrointestinal smooth muscle (72, 84).  The 
increase in the expression of smoothelin-A in colitis suggests that it may be a compensatory 
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mechanism to offset the inhibitory effects exerted by increased caldesmon and calponin on 
smooth muscle contraction.   
The results also suggest that up-regulation of thin-filament associated proteins is due to changes 
in the transcriptional regulation of these proteins, probably via the direct effect of 
proinflammatory cytokines on the transcription factors.  Previous studies demonstrated that 
exposure of cultured muscle cells to IL-1β or TNF-α caused change in the transcriptional 
regulation of several proteins involved in smooth muscle contraction (31, 32, 93-96).  The 
decrease in contraction on exposure of smooth muscle to IL-1β or TNF-α was reversed by 
inhibitor of nuclear factor-kappa B (NF-B), suggesting that the cytokine effects are mediated 
mainly by NF-B.  Future studies on the animal models combined with studies on the smooth 
muscle cultures exposed to proinflammatory cytokines should provide valuable information on 
the direct effects of cytokines on the smooth muscle contractile proteins.   
The final common pathway in the regulation of colon motility is the contractility of colonic 
muscle. This can be evaluated in vitro using isolated muscle cell preparation. Our studies in 
isolated muscle cells demonstrate that contraction induced by acetylcholine is decreased in both 
model of colitis.  Clearly, changes in muscle contraction observed in vitro should be extrapolated 
into the in vivo situation with caution.  Consideration must be given to the important roles 
mediated by enteric nerves, the ICC, and other endocrine and paracrine factors.  In addition, the 
roles of circular and longitudinal muscle differ in terms of their contribution to peristaltic activity 
and their response to inflammation.  However, muscle contraction is an acceptable approach and 
important determinant of evaluating how inflammatory and immune cells affect colonic motility. 
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In summary, the results of the present study have demonstrated colitis-augmented the 
expression of -actin, γ-actin, tropomyosin and smoothelin and the that the decrease in the 
contraction of smooth muscle isolated from colitis mouse colon is attributable to the increase in 
thin-filament associated proteins.  Whether the changes in the expression of smooth muscle 
markers and the decrease of contraction are the cause or the consequence of disturbed GI tract 
motility remains to be determined.   The changes smooth muscle contractile proteins, assessed 
here in inflammation, appear appropriate to associate to the functional alterations of the smooth 
muscle cell, and this was not studied before.  A relatively minor role under physiological 
condition may a determining factor contributing to dysfunction of smooth muscle in diseases.  In 
deed, changes in the expression of contractile proteins were demonstrated in various 
pathophysiological situations.  Future studies of the mechanisms involved in the up-regulation of 
these proteins might provide more understanding of the molecular pathways involved in the 
expression of contractile protein regulation.  Targeting these pathways in the regulation of 
colonic muscle contraction would be interesting.  Clearly, a comprehensive appraisal of the 
enteric muscle contractile proteins and signal transduction pathways, in addition to the 
evaluation of enteric neurons and ICC, may contribute to further characterization of mechanisms 
underlying gastrointestinal motility disorders. 
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